【医疗研报】艾昆纬-制药公司的冻结资产-冷链药品（英）-2023.1_市场营销策划_2023年医疗医.docxVIP

White Paper Pharma’s Frozen Assets Cold chain medicines STEFAN LUTZMAYER, Consultant, EMEA Thought Leadership, IQVIA Table of contents Introduction 3 Approach to defining cold chain medicines 5 The cold chain market: a global overview 6 Vaccines – a high-volume cold chain market 8 Logistical challenges around next-generation biotherapeutics 9 Implications for pharma and logistics companies 10 Conclusion 12 References 13 About the authors 14 Acknowledgment 15 PAGE PAGE 4 | Pharma’s Frozen Assets: Cold Chain Medicines | PAGE 11 Introduction A huge and lingering logistical challenge in delivering vaccines globally during the pandemic has been in scaling up the refrigerated networks that make up part of the global “cold chain” — the uninterrupted process of maintaining end-to-end temperature-controlled conditions from the manufacturing site to the point of care. Cold chain medicines require more energy than their ambient temperature counterparts. If pharmaceutical companies want to live up to their ambitious environmental, social and governance (ESG) targets, they will need to understand current and future trends and work closely with logistics companies to ensure delivery of often live-saving cold chain medicines whilst having their CO2 footprint in mind. Healthcare is contributing an estimated 4.2% of the global carbon footprint.1 The share of pharmaceuticals is significant. Studies conducted in the UK and France report medicines’ share of total health systems’ emission to be 25% and 33% respectively.2,3 As part of environmental, social and governance (ESG) goals, pharma wants to become greener. In addition to reaching environmental targets, the recent sharp rise in gas prices and resulting high inflation make saving energy also an economic imperative. Natural gas prices increased by 139% in the first half of 2022 compared to the previous year.4 Pharma manufacturers face a 400–500% and 100-200% rise in costs for shipping containers and